The Latest Breaking News from LNTH

Dow Jones futures: The market rally ramped up as big banks backed First Republic, but needs to do this. FedEx is set to break out on earnings. Apple and Microsoft are buys.

Lantheus Holdings is Thursday's IBD Stock Of The Day. The small player is making a big impact in prostate cancer, and LNTH stock is soaring.

With medical imaging leader Lantheus driving AI innovations and massive 1,840% growth, LNTH stock takes aim at a fresh breakout.

Once again, stocks rallied off lows, as hawkish Fed members took a dovish tone. But it's a tough market. Tesla rival BYD jumped on guidance.

The market rally faces a test amid renewed China concerns. Tesla CEO Elon Musk moved to end the Twitter takeover.

Lantheus Holdings is the IBD Stock Of The Day as LNTH stock consolidates following a monstrous run-up that began in February.

Lantheus Holdings, Inc. (NASDAQ: LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells. NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.

According to Benzinga Pro, during Q1, Lantheus Holdings (NASDAQ:LNTH) earned $42.96 million, a 206.83% increase from the preceding quarter. Lantheus Holdings also posted a total of $208.88 million in sales, a 61.22% increase since Q4.

  Lantheus Holdings (NASDAQ:LNTH) reported its Q1 earnings results on Friday, April 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement.